| Cell line name |
OV-MZ-38 |
|---|
| Synonyms |
OVarian-MainZ-38 |
|---|
| Accession |
CVCL_X961 |
|---|
| Resource Identification Initiative |
To cite this cell line use: OV-MZ-38 (RRID:CVCL_X961) |
|---|
| Comments |
Derived from site: In situ; Ovary; UBERON=UBERON_0000992. |
|---|
| Sequence variations |
|
|---|
| Disease |
Ovarian serous cystadenocarcinoma (NCIt: C7978) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
56Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=11242531; DOI=10.1089/10430340150504019
Ansgar Bruning, Tanja Kohler, Sven Roy Quist, Shan Wang-Gohrke, Volker Jochen Mobus, Rolf Kreienberg, Ingo Bernard Runnebaum;
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001) PubMed=11925137; DOI=10.1006/gyno.2002.6597
Matthias Oppitz, Volker Jochen Mobus, S. Brock, Ulrich Drews;
Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients.
Gynecol. Oncol. 85:159-164(2002) PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Sven Roy Quist, Shan Wang-Gohrke, Tanja Kohler, Rolf Kreienberg, Ingo Bernard Runnebaum;
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54936864
|
|---|
| Entry history |
|---|
| Entry creation | 05-Sep-2014 |
|---|
| Last entry update | 27-Nov-2025 |
|---|
| Version number | 9 |
|---|
